Results of a prospective, mixed methods study to assess feasibility, acceptability and effectiveness of TRIumPH (Treatment and Recovery In PsycHosis): an integrated care pathway for psychosis, compared to usual treatment.
Adult
Delivery of Health Care, Integrated
Early Medical Intervention
England
Feasibility Studies
Female
Focus Groups
Humans
Length of Stay
Male
Outcome Assessment, Health Care
Patient Discharge
Prospective Studies
Psychotic Disorders
/ prevention & control
Recovery of Function
Schizophrenia
/ prevention & control
Secondary Prevention
/ methods
Time-to-Treatment
Treatment Outcome
Young Adult
adult psychiatry
early intervention
integrated care pathways
schizophrenia & psychotic disorders
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
29 04 2020
29 04 2020
Historique:
entrez:
2
5
2020
pubmed:
2
5
2020
medline:
13
2
2021
Statut:
epublish
Résumé
To evaluate whether a newly developed care pathway, Treatment and Recovery In PsycHosis (TRIumPH), is feasible, acceptable and effective in meeting National Institute of Health and Care Excellence (NICE) quality standards in a timely manner. This is a pragmatic, non-randomised, prospective, mixed methods study comparing an implementation (TRIumPH) and comparator site (not implementing TRIumPH) across three cohorts to assess feasibility, acceptability and effectiveness of the integrated pathway. Early intervention in psychosis (EIP) services at two National Health Service organisations in South of England. All patients accepted into EIP services between 1 June 2014 and 31 May 2017 were each followed up for 1 year within their respective cohorts. Quantitative data consisted of routinely collected clinical data retrieved from patient records to assess whether the implementation of TRIumPH achieved better concordance to NICE standards. These included time to access services, physical health assessments, clinical outcomes based timeliness of delivery and acute data. The controlled trial has evaluated the effect of TRIumPH (Intervention) with Care As Usual (Comparator). Qualitative measures consisted of questionnaires, interviews and focus groups to assess acceptability and satisfaction. Outcome measures were compared within the baseline, year 1 and year 2 cohorts and between the two sites. Quantitative data were statistically analysed by comparing means and proportions. Time to assessment improved in the implementation site and remained within the target in comparator site. Meeting of quality standards increased substantially in the implementation site but was more variable and reached lower levels in the comparator site especially for physical health standards. Cognitive therapy for psychosis, family intervention and carer and employment support were all offered to a greater extent in the implementation site and uptake increased over the period. Pathway implementation generally led to greater improvements in achievement of access and quality standards compared with comparator site. UK Clinical Research Network Portfolio (19187).
Identifiants
pubmed: 32354777
pii: bmjopen-2019-033711
doi: 10.1136/bmjopen-2019-033711
pmc: PMC7213857
doi:
Types de publication
Comparative Study
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e033711Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: The production of the pathway has been supported by the Wessex Academic Health Sciences Network (AHSN) and evaluation has been supported by the Wessex Clinical Research Network (CRN). The views and opinions expressed herein are those of the authors and do not necessarily reflect those of funders, NIHR, NHS or the RCPsych, AHSN or CRN. The study is sponsored by Southern Health NHS Foundation Trust.
Références
BMJ Open. 2016 Dec 21;6(12):e012751
pubmed: 28003288
BMJ. 1998 Jan 10;316(7125):133-7
pubmed: 9462322
Eur Neuropsychopharmacol. 2005 Aug;15(4):399-409
pubmed: 15925493
Br J Psychiatry. 2000 Dec;177:511-5
pubmed: 11102325
PLoS One. 2011;6(5):e19590
pubmed: 21611123
Early Interv Psychiatry. 2012 Nov;6(4):423-31
pubmed: 22225572
Biol Psychiatry. 1999 Oct 1;46(7):899-907
pubmed: 10509173
Br J Psychiatry. 2014 Aug;205(2):88-94
pubmed: 25252316
Arch Gen Psychiatry. 2005 Sep;62(9):975-83
pubmed: 16143729
Br J Psychiatry. 2013 Jul;203(1):58-64
pubmed: 23703317